Expression analyses in different cohorts of AML samples revealed 17 of the hub genes (ABCA13, ANXA3, ARG1, BTNL8, C11orf42, CEACAM1, CEACAM3, CHI3L1, CRISP2, CYP4F3, GPR84, HP, LTF, MMP8, OLR1, PADI2, RGL4, and RILPL1) were downregulated in AML PB samples compared to healthy whole blood samples; ANXA3, CEACM1, RGL4, RILPL1, and HP showed increased expression levels in AML BM samples of the posttreatment stage compared to the diagnosis and/or recurrent stage. The gene discussed is CEACAM3; the disease is acute myeloid leukemia.